Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Evaluation of Soluble ST2 in Patients Receiving Primary PCI With ST-elevation Myocardial Infarction

Conditions:   Myocardial Infarction;   Shock
Intervention:  
Sponsor:   Wuhan Asia Heart Hospital
Recruiting - verified July 2016

Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis

Conditions:   Myocardial Infarction;   Influenza, Human;   Influenza Vaccines;   Heart Failure;   Stroke
Interventions:   Biological: Influenza vaccine;   Biological: Placebo
Sponsors:   Ole Frobert, MD, PhD;   Swedish Heart Lung Foundation;   Sanofi Pasteur, a Sanofi Company;   Uppsala University;   Lytics
Not yet recruiting - verified July 2016

The Northwest Coalition for Primary Care Practice Support

Conditions:   Cardiovascular Disease;   Essential Hypertension;   Nicotine Dependence;   Hyperlipidemia
Interventions:   Other: Coaching;   Other: Educational Outreach;   Other: Site Visits
Sponsors:   Group Health Cooperative;   University of Washington;   Oregon Health and Science University
Active, not recruiting - verified July 2016

" Endarterectomy Combined With Optimal Medical Therapy Versus Optimal Medical Therapy Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke "

Condition:   Asymptomatic Carotid Stenosis at Higher-than-average Risk of Ipsilateral Stroke
Interventions:   Other: Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT);   Drug: Optimal medical therapy alone
Sponsors:   Centre Hospitalier St Anne;   Hôpitaux Universitaires Paris Ile-de-Franc Ouest
Not yet recruiting - verified July 2016

The TRUST Study - CardioVascular Imaging IMT

Conditions:   Thyroid Dysfunction;   Atherosclerosis;   Heart Failure
Interventions:   Drug: Levothyroxine;   Drug: Placebo
Sponsors:   University Hospital Inselspital, Berne;   University of Lausanne Hospitals;   University Hospital, Geneva
Recruiting - verified July 2016

The TRUST Trial - CardioVascular Imaging ECHO

Conditions:   Thyroid Dysfunction;   Atherosclerosis;   Heart Failure
Interventions:   Drug: Levothyroxine;   Drug: Placebo
Sponsors:   University Hospital Inselspital, Berne;   University of Lausanne Hospitals;   University Hospital, Geneva
Recruiting - verified July 2016

3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation

Condition:   Coronary Artery Disease
Interventions:   Drug: Aspirin;   Drug: Thienopyridine
Sponsor:   Teikyo University
Not yet recruiting - verified July 2016

Retrospective Study of Acute Chest Pain in Extremely Critical Condition for More Than Ten Years

Condition:   Chest Pain in Extremely Critical Condition
Intervention:  
Sponsor:   Qilu Hospital
Recruiting - verified July 2016

Evaluation of Emotional Status and Coronary Flow Characteristics by TIMI Frame Count Method

Conditions:   Coronary Artery Disease;   Coronary Artery Ectasia;   Slow-Flow Phenomenon;   Endothelial Dysfunction;   Anxiety;   Depression
Intervention:   Procedure: coronary angiography
Sponsors:   Ertan YETKIN;   Abant Izzet Baysal University;   Gulhane Military Medical Academy;   Ankara Numune Training and Research Hospital;   Private Yenisehir Hospital;   Private Gozde Hospital;   Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Recruiting - verified July 2016

Relation Between NLR and IMR in STEMI Patients

Conditions:   Myocardial Infarction;   Death
Intervention:  
Sponsor:   Inha University Hospital
Completed - verified June 2016

Diabetes Complication Control in Community Clinics (D4C) Trial

Conditions:   Diabetes;   Hypertension;   Dyslipidemia;   Cardiovascular Disease
Intervention:   Other: Protocol-based integrated care
Sponsors:   Tulane University Health Sciences Center;   Xiamen Diabetes Institute, Xiamen University, Xiamen, China
Not yet recruiting - verified July 2016

Reactive Oxygen Species Following Aortic Valve Replacement

Condition:   Aortic Stenosis
Intervention:  
Sponsor:   University Hospital Southampton NHS Foundation Trust.
Recruiting - verified July 2016

Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention

Conditions:   Myocardial Infarction;   Complications; Device, Vascular;   Injury of Radial Artery;   Injury; Blood Vessel, Femoral, Artery
Interventions:   Procedure: Transradial primary percutaneous coronary intervention;   Procedure: Transfemoral primary percutaneous coronary intervention
Sponsor:   Irmandade Santa Casa Misericórdia Marília
Recruiting - verified July 2016

PPI's and SSRI's Therapy for the Management of NCCP

Condition:   Chest Pain Rule Out Myocardial Infarction
Intervention:   Drug: Citalopram
Sponsor:   Evangelismos Hospital
Recruiting - verified July 2016

TRANscatheter or SurgIcal Aortic Valve ReplacemenT in All-Comers With Severe Aortic Valve Stenosis

Condition:   Aortic Valve Stenosis
Interventions:   Device: SAPIEN 3;   Procedure: SAVR
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified July 2016

Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease

Condition:   Percutaneous Transluminal Coronary Angioplasty
Interventions:   Device: everolimus-eluting bioresorbable vascular (Absorb) scaffold;   Device: everolimus-eluting cobalt-chromium (Xience) stent
Sponsors:   Duk-Woo Park;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified July 2016

Quantitative Coronary Angiography Versus Imaging GUIDancE for Bioresorbable Vascular Scaffold Implantation

Condition:   Percutaneous Transluminal Coronary Angioplasty
Interventions:   Procedure: QCA and Aspirin;   Procedure: QCA and Clopidogrel;   Procedure: Imaging guided and Aspirin;   Procedure: Imaging guided and Clopidogrel
Sponsors:   CHEOL WHAN LEE, M.D., Ph.D;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified July 2016

The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI

Condition:   Acute ST Elevation Myocardial Infarction
Interventions:   Drug: rhTNK-tPA;   Drug: alteplase
Sponsors:   Guangzhou Recomgen Biotech Co., Ltd.;   Chinese Academy of Medical Sciences, Fuwai Hospital;   Peking University
Active, not recruiting - verified July 2016

Assessment Of Total Coronary Circulation Time Using TIMI Frame Count Method (TCCT-TIMI)

Conditions:   Coronary Angiography;   Coronary Artery Disease;   Coronary Artery Ectasia;   Slow-Flow Phenomenon;   Coronary Heart Disease
Intervention:   Procedure: coronary angiography
Sponsors:   Vascular and Molecular Cardiology Society;   Private Yenisehir Hospital;   Private Gozde Hospital;   Gulhane Military Medical Academy
Recruiting - verified July 2016

The Effect of Remote Ischemic Preconditioning on Major Organ Function in Patients With Coronary Artery Disease Undergoing Orthopedic Surgery

Conditions:   Angina Pectoris;   Myocardial Infarction
Interventions:   Procedure: Remote ischemic preconditioning;   Procedure: Sham control
Sponsor:   Seoul National University Hospital
Recruiting - verified July 2016

A Study of Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications

Conditions:   Hemorrhage, Gastrointestinal;   Myocardial Infarction;   Stroke;   Kidney Diseases
Intervention:  
Sponsor:   Janssen Research & Development, LLC
Active, not recruiting - verified July 2016

Naloxegol Health Outcomes PASS

Condition:   Opioid Induced Constipation
Interventions:   Drug: naloxegol;   Drug: non-PAMORA laxative
Sponsor:   AstraZeneca
Not yet recruiting - verified July 2016

Efficacy of Aspirin and L-arginine in High Risk Preeclamptic

Condition:   High Risk Pregnancy
Interventions:   Drug: L-arginine;   Drug: Placebo (for L-arginine);   Drug: acetylsalicylic acid
Sponsors:   University of Guadalajara;   PhD Ernesto Javier Ramírez Lizardo;   PhD Sylvia Elena Totsuka Sutto;   PhD Fernando Grover Páez;   MD Diego Hernández Molina
Not yet recruiting - verified July 2016

Circulating PRCP in STEMI Patients Undergoing Primary PCI

Conditions:   Myocardial Infarction;   Percutaneous Coronary Intervention;   PRCP
Intervention:   Procedure: Primary PCI
Sponsor:   Qilu Hospital
Completed - verified July 2016

Tele-Health Electronic Monitoring to Reduce Post Discharge Complications and Surgical Site Infections

Condition:   Peripheral Vascular Disease
Intervention:   Other: Tele-Health Electronic Monitoring (THEM)
Sponsors:   CAMC Health System;   WVCTSI
Enrolling by invitation - verified July 2016

Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

Condition:   Normal Physiology
Interventions:   Drug: Solu-Medrol (methylprednisolone sodium succinate);   Drug: Topical methylprenisolone 0.1%
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified July 2016

Self-apposing Stentys Stents Registry

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   Azienda Ospedaliera Città della Salute e della Scienza di Torino
Not yet recruiting - verified July 2016

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL_112;   Other: Placebo
Sponsor:   CSL Behring
Not yet recruiting - verified July 2016

IRIS-BVS AMI Registry

Conditions:   Arterial Occlusive Diseases;   Cardiovascular Diseases;   Coronary Artery Disease
Intervention:   Device: Bioresorbable Vascular Scaffold
Sponsors:   CHEOL WHAN LEE, M.D., Ph.D;   CardioVascular Research Foundation, Korea
Recruiting - verified July 2016

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified May 2016

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified July 2016

Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis

Condition:   Stable Angina
Intervention:   Device: Drug-eluting stent
Sponsors:   Seoul National University Hospital;   Ajou University School of Medicine;   Keimyung University Dongsan Medical Center;   Inje University
Recruiting - verified July 2016

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Condition:   Thrombosis
Interventions:   Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2016

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority

Condition:   Rheumatic Heart Disease
Interventions:   Drug: Rivaroxaban (15 mg);   Drug: Aspirin
Sponsors:   Population Health Research Institute;   University of Cape Town
Not yet recruiting - verified July 2016

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified July 2016

Coronariography in OUt of hosPital Cardiac arrEst

Condition:   Cardiac Arrest
Interventions:   Procedure: Urgent Coronary Angiography;   Procedure: Deferred Coronary Angiography
Sponsors:   Hospital San Carlos, Madrid;   Hospital Clínico Universitario de Valladolid;   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau;   Hospital Vall d'Hebron;   Hospital Arnau de Vilanova;   Hospital Universitari de Bellvitge;   Hospital General Universitario Gregorio Marañon;   Institut d Investigación Biomedica Dr. Josep Trueta de Girona
Recruiting - verified July 2016

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority

Condition:   Rheumatic Heart Disease
Interventions:   Drug: Rivaroxaban (20 mg);   Drug: Vitamin K antagonists (VKA)
Sponsors:   Population Health Research Institute;   University of Cape Town
Not yet recruiting - verified July 2016

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

Condition:   Coronary Artery Disease
Interventions:   Drug: 1-month DAPT;   Drug: 12-month DAPT
Sponsor:   Kyoto University, Graduate School of Medicine
Recruiting - verified July 2016

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified July 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified July 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified July 2016

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified July 2016

COOL AMI EU Pilot Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Device: Cooling + PCI;   Device: PCI only
Sponsor:   ZOLL Circulation, Inc., USA
Recruiting - verified July 2016

Follow-up of Patients Bound for PCI After Implementation of a Helicopter Emergency Medical System

Condition:   ST-elevation Myocardial Infarction
Intervention:   Other: Helicopter Emergency Medical Service
Sponsors:   Rigshospitalet, Denmark;   TrygFonden, Denmark
Completed - verified July 2016

Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction

Condition:   ST Segment Elevation Myocardial Infarction
Intervention:  
Sponsor:   Intermountain Health Care, Inc.
Recruiting - verified June 2016

Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2

Condition:   Non-valvular Atrial Fibrillation
Intervention:  
Sponsors:   Bristol-Myers Squibb;   IMS Health;   Oxon Epidemiology
Active, not recruiting - verified July 2016

Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Ischemic Stroke;   Transient Ischemic Attack
Interventions:   Device: Single lead ECG device;   Device: 7-Day Holter monitor.
Sponsors:   Leiden University Medical Center;   Medical Center Haaglanden;   Groene Hart Ziekenhuis;   Herning Hospital;   Bronovo Hospital
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified July 2016

CardiAMP™ Heart Failure Trial

Condition:   Heart Failure
Interventions:   Biological: Autologous cell therapy;   Device: CardiAMP cell therapy;   Other: Sham
Sponsor:   BioCardia, Inc.
Not yet recruiting - verified July 2016

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection

Condition:   Asthma
Interventions:   Drug: Interferon beta-1a Nebuliser solution 48 μg/mL;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified July 2016

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified May 2016

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome,
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Recruiting - verified July 2016

Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling Device

Condition:   Traumatic Brain Injury
Intervention:   Device: Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.
Sponsors:   Advanced Cooling Therapy, LLC;   Dnipropetrovsk State Medical Academy
Recruiting - verified July 2016

Brilinta Taiwan Post Approval Safety Study

Condition:   Non ST-elevation Myocardial Infarction
Intervention:   Drug: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Sponsor:   AstraZeneca
Active, not recruiting - verified July 2016

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Conditions:   Coronary Artery Disease;   Atherosclerosis, Coronary;   Myocardial Ischemia;   Ischemic Heart Disease;   Acute Coronary Syndrome;   Angina Pectoris
Interventions:   Device: Orsiro DES;   Device: Xience DES
Sponsors:   Biotronik, Inc.;   Biotronik AG;   Harvard Clinical Research Institute;   Medstar Research Institute
Active, not recruiting - verified July 2016

The Health Impact of High Intensity Exercise Training With Intervals During Cardiac Rehabilitation

Conditions:   Heart Disease;   Heart Attacks
Interventions:   Other: High intensity interval training (HIIT);   Other: Standard care
Sponsors:   Liverpool Heart and Chest Hospital NHS Foundation Trust;   Edge Hill University
Recruiting - verified July 2016

Validation of Simple Acute Coronary Syndrome (SACS) Score

Conditions:   Chest Pain;   Acute Coronary Syndrome;   Angina;   Myocardial Infarction
Intervention:  
Sponsors:   Bayfront Health St Petersburg;   Bayfront Health Dade City;   Community Health Systems (CHS)
Enrolling by invitation - verified July 2016

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified July 2016

Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia

Conditions:   Complex Endometrial Hyperplasia With Atypia;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer
Interventions:   Behavioral: Weight Loss Specialist;   Other: Quality-of-Life Assessment;   Other: Medical Chart Review
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified July 2016

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

Condition:   Systemic Lupus Erthematosus
Interventions:   Radiation: PET/CT;   Drug: Pioglitazone;   Procedure: Vascular function studies
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified February 2016

Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)

Conditions:   Acute Kidney Injury;   Renal Insufficiency
Intervention:   Procedure: cardiac surgery
Sponsor:   Baylor Research Institute
Active, not recruiting - verified July 2016

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified July 2016

Combined Coronary and Cerebral Angiography and Intervention for Coronary and Cerebrovascular Atherosclerosis

Conditions:   Coronary Stenosis;   Cerebral Stenosis
Interventions:   Other: simultaneous coronary and cerebral intervention;   Other: staged coronary and cerebral intervention
Sponsor:   Capital Medical University
Recruiting - verified July 2016

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Recruiting - verified July 2016

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2016

Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis

Conditions:   Acute ST Segment Elevation Myocardial Infarction;   Thrombolysis in Myocardial Infarction Flow
Interventions:   Drug: Ticagrelor 180 mg;   Drug: Clopidogrel
Sponsor:   Hospital do Coracao
Recruiting - verified July 2016

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified July 2016

REPARA Study: REgistry of PAtients With bioResorbable Device in Daily Clinical prActice

Condition:   Coronary Artery Lesions With Implantation of Coronary Device
Intervention:  
Sponsor:   Sección Hemodinamica y Cardiologia Intervencionista
Active, not recruiting - verified July 2016

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.

Condition:   Polycythemia Vera
Intervention:   Drug: Pegylated-Proline-interferon alpha-2b
Sponsors:   AOP Orphan Pharmaceuticals AG;   PharmaEssentia (Co-Sponsor for USA)
Active, not recruiting - verified July 2016

Intravascular Ultrasound Guided Drug Eluting Stent Implantation in "All-comers" Coronary Lesions

Condition:   Coronary Artery Disease
Interventions:   Procedure: Angiography;   Procedure: IVUS;   Procedure: DES implantation
Sponsor:   The First Affiliated Hospital with Nanjing Medical University
Recruiting - verified July 2016

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

3D Multi-Contrast Atherosclerosis Characterization of the Carotid Artery

Condition:   Carotid Artery Disease
Intervention:   Other: MRI with/without contrast
Sponsors:   Cedars-Sinai Medical Center;   National Heart, Lung, and Blood Institute (NHLBI);   American Heart Association
Recruiting - verified July 2016

Is the 4MGS a Useful Outcome Measure Post-PPCI

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsors:   Royal Brompton & Harefield NHS Foundation Trust;   Medical Research Council
Active, not recruiting - verified July 2016

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Conditions:   Heart Failure;   Respiratory Insufficiency;   Stroke Acute;   Infectious Diseases;   Rheumatic Diseases
Interventions:   Drug: Rivaroxaban, 10 mg;   Drug: Rivaroxaban, 7.5 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified July 2016

Detection and Significance of Heart Injury in ST Elevation Myocardial Infarction.

Condition:   Acute ST-elevation Myocardial Infarction
Interventions:   Device: Coronary pressure wire;   Other: Magnetic resonance imaging of the heart
Sponsors:   NHS National Waiting Times Centre Board;   Siemens Healthcare Diagnostics Inc;   British Heart Foundation
Active, not recruiting - verified July 2016

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

IRIS-PREMIER REGISTRY

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Coronary Disease;   Heart Diseases
Intervention:   Device: Promus PREMIER
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Boston Scientific Korea Co. Ltd
Active, not recruiting - verified July 2016

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:   Drug: Observational
Sponsor:   Boehringer Ingelheim
Completed - verified July 2016

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)

Conditions:   Hypertension;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified July 2016

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

Condition:   Saphenous Vein Graft Disease
Interventions:   Drug: Aspirin;   Drug: Ticagrelor
Sponsors:   Boca Raton Regional Hospital;   AstraZeneca;   Ottawa Heart Institute Research Corporation
Recruiting - verified July 2016

Nelfinavir in Systemic Lupus Erythematosus

Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Nelfinavir
Sponsors:   Northwell Health;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified July 2016

Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction

Conditions:   Coronary Artery Disease;   Acute Myocardial Infarction With ST-segment Elevation;   Primary Percutaneous Coronary Intervention;   Early Discharge
Interventions:   Other: Early discharge;   Other: Standard discharge
Sponsor:   Kamil Novobílský
Recruiting - verified July 2016

Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation

Conditions:   Ischemic Stroke;   Transient Ischemic Attack
Interventions:   Drug: Rivaroxaban;   Drug: Warfarin
Sponsors:   Asan Medical Center;   Bayer
Completed - verified July 2016

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Conditions:   Cardiovascular Disease;   High Cardiovascular Risk;   Obesity;   Overweight;   Type 2 Diabetes
Interventions:   Drug: APD356-Lorcaserin hydrochloride;   Drug: Placebo
Sponsors:   Eisai Inc.;   Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
Active, not recruiting - verified July 2016

STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial

Conditions:   Anterior Acute Myocardial Infarction;   Left Ventricular Systolic Dysfunction
Intervention:   Drug: G-CSF administration
Sponsors:   Heart Care Foundation;   A. Manzoni Hospital;   Centro Cardiologico Monzino
Suspended - verified March 2015

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified July 2016

To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels

Conditions:   Coronary Disease;   Coronary Artery Disease;   Coronary Restenosis
Intervention:   Device: Absorb BVS
Sponsor:   Abbott Vascular
Active, not recruiting - verified July 2016

COOL-AMI EU Case Series Clinical Study

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   ZOLL Circulation, Inc., USA
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified July 2016

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified July 2016

Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure

Condition:   Ischemic Cardiomyopathy
Interventions:   Procedure: Percutaneous Coronary Intervention;   Drug: Drug Therapy for Heart Failure;   Device: Device Therapy for Heart Failure
Sponsors:   King's College London;   National Institute for Health Research, United Kingdom;   London School of Hygiene and Tropical Medicine (Clinical Trials Unit);   University of York;   Guy's and St Thomas' NHS Foundation Trust
Recruiting - verified July 2016

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

Condition:   Peripheral Endovascular Interventions
Intervention:   Drug: Bivalirudin
Sponsor:   The Medicines Company
Active, not recruiting - verified July 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Conditions:   Heart Failure;   Coronary Artery Disease
Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified July 2016

Conservative Non-Invasive Versus Routine Invasive Management in Coronary Artery Bypass Surgery Patients With Non ST Elevation Elevation Acute Coronary Syndrome

Conditions:   Non ST Elevation Myocardial Infarction;   Unstable Angina
Intervention:   Procedure: Invasive management
Sponsors:   NHS National Waiting Times Centre Board;   University of Glasgow
Completed - verified July 2016

Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study

Condition:   Acute ST Segment Elevation Myocardial Infarction
Interventions:   Device: PCI in patients with ST-elevation myocardial infarction;   Device: PCI in patients with ST-elevation myocardial infarction
Sponsor:   Terumo Europe N.V.
Active, not recruiting - verified July 2016

OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON

Condition:   Coronary Artery Disease
Interventions:   Device: OFDI;   Device: IVUS
Sponsors:   Translational Research Informatics Center, Kobe, Hyogo, Japan;   Wakayama Medical University
Completed - verified July 2016

Study Of Diabetic Nephropathy With Atrasentan

Condition:   Diabetic Nephropathy
Interventions:   Drug: Atrasentan;   Drug: Placebo
Sponsor:   AbbVie
Recruiting - verified July 2016

Chronic Remote Ischemic Conditioning to Modify Post-MI Remodeling

Condition:   Myocardial Infarction
Intervention:   Device: Auto Remote Ischemic Conditioning (AutoRIC) device
Sponsors:   The Hospital for Sick Children;   University Health Network, Toronto;   Sunnybrook Health Sciences Centre;   St. Michael's Hospital, Toronto
Recruiting - verified July 2016

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention &Amp; Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified July 2016

Fractional Flow Reserve Versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes

Conditions:   Non-ST Elevation Myocardial Infarction.;   Type 1 Myocardial Infarction.
Intervention:   Device: Fractional flow reserve
Sponsors:   NHS National Waiting Times Centre Board;   British Heart Foundation;   St. Jude Medical;   University of Glasgow
Active, not recruiting - verified July 2016

Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)

Condition:   Acute Coronary Syndrome
Intervention:   Drug: P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Sponsor:   Samsung Medical Center
Recruiting - verified July 2016

Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure

Condition:   Heart Failure
Intervention:   Biological: intracoronary infusion of autologous bone marrow-derived cells
Sponsor:   Johann Wolfgang Goethe University Hospitals
Recruiting - verified July 2016

A Study of Evacetrapib in High-Risk Vascular Disease

Condition:   Cardiovascular Diseases
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   The Cleveland Clinic
Active, not recruiting - verified July 2016

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: Placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified July 2016

PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease

Conditions:   Chronic Kidney Disease;   Diabetes
Intervention:   Drug: Darbepoetin alfa
Sponsors:   Translational Research Informatics Center, Kobe, Hyogo, Japan;   Showa University School of Medicine
Active, not recruiting - verified July 2016

The Supplementary Role of Non-invasive Imaging to Routine Clinical Practice in Suspected Non-ST-elevation Myocardial Infarction

Conditions:   Chest Pain;   Myocardial Infarction;   Acute Coronary Syndrome;   Coronary Artery Disease;   Myocardial Ischemia
Interventions:   Other: Cardiovascular Magnetic Resonance Imaging;   Other: Computed Tomography Angiography
Sponsors:   Maastricht University Medical Center;   Dutch Heart Foundation
Active, not recruiting - verified July 2016

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

Condition:   Saphenous Vein Graft Disease
Interventions:   Drug: Atorvastatin 80 mg daily;   Drug: Atorvastatin 10 mg daily
Sponsors:   Boca Raton Regional Hospital;   Pfizer
Active, not recruiting - verified July 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

Vest Prevention of Early Sudden Death Trial and VEST Registry

Conditions:   Myocardial Infarction;   Ventricular Dysfunction;   Sudden Death;   Ventricular Tachycardia;   Ventricular Fibrillation
Intervention:   Device: wearable defibrillator
Sponsors:   University of California, San Francisco;   Zoll Medical Corporation
Recruiting - verified July 2016

ABSORB II Randomized Controlled Trial

Condition:   Coronary Artery Disease
Interventions:   Device: Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System;   Device: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
Sponsor:   Abbott Vascular
Active, not recruiting - verified July 2016

Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Condition:   Leukemia
Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
Active, not recruiting - verified July 2016

Acute Coronary Syndrome and Care-Seeking Delay: A Web Based Behavioral Study

Conditions:   Acute Myocardial Infarction;   Heart Attack;   Acute Coronary Syndrome;   Unstable Angina
Intervention:  
Sponsors:   Yale University;   Ohio State University
Completed - verified July 2016

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

Condition:   Non-ischemic Dilated Cardiomyopathy
Interventions:   Procedure: Transendocardial injection;   Biological: Autologous hMSCs;   Biological: Allogeneic hMSCs
Sponsors:   Joshua M Hare;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified July 2016

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Condition:   Myocardial Infarction
Interventions:   Procedure: Percutaneous Coronary Intervention (PCI);   Drug: RO4905417;   Drug: RO4905417;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2016

Identification of Genomic Predictors of Adverse Events After Cardiac Surgery

Conditions:   Heart; Dysfunction Postoperative, Cardiac Surgery;   Genetic Predisposition to Disease;   Atrial Fibrillation;   Myocardial Infarction;   Heart Failure
Intervention:  
Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   Texas Heart Institute;   University of Texas Southwestern Medical Center
Recruiting - verified July 2016

EXCEL Clinical Trial

Conditions:   Chronic Coronary Occlusion;   Unprotected Left Main Coronary Artery Disease;   Stent Thrombosis;   Vascular Disease;   Myocardial Ischemia;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Artery Disease;   Coronary Restenosis
Interventions:   Device: Percutaneous Coronary Intervention;   Procedure: CABG
Sponsor:   Abbott Vascular
Active, not recruiting - verified July 2016

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Condition:   Cardiovascular Disease
Interventions:   Drug: Febuxostat;   Drug: Allopurinol
Sponsors:   Takeda;   Teijin America, Inc.
Recruiting - verified July 2016

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified July 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2016

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Condition:   Ischemic Attack, Transient
Interventions:   Drug: Clopidogrel;   Drug: placebo
Sponsors:   University of California, San Francisco;   Neurological Emergencies Treatment Trials Network (NETT);   Medical University of South Carolina;   The EMMES Corporation
Recruiting - verified July 2016

Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy

Condition:   Recurrent Ventricular Tachycardia
Interventions:   Procedure: Catheter Ablation;   Drug: Escalated Antiarrhythmic Therapy
Sponsors:   John Sapp;   St. Jude Medical;   Biosense Webster, Inc.;   Canadian Institutes of Health Research (CIHR)
Completed - verified July 2016

The Clinical Evaluation of the Dose of Erythropoietins Trial

Condition:   Kidney Failure, Chronic
Interventions:   Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.;   Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.
Sponsor:   Giovanni FM Strippoli, MD
Completed - verified July 2016

Natural Killer Cells and Bortezomib to Treat Cancer

Conditions:   Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention:   Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2016

Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.

Conditions:   Contraception;   Female Contraception;   Fertility Control
Intervention:  
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Boston Collaborative Drug Surveillance Program
Completed - verified July 2016

A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control

Conditions:   Contraception;   Female Contraception
Interventions:   Drug: Transdermal Contraceptive System;   Drug: Norgestimate-containing oral contraceptives with EE
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified July 2016

Genetic Factors in Atherosclerosis

Condition:   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed - verified March 2013

Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks

Conditions:   Contraception;   Female Contraception
Interventions:   Drug: Monophasic or triphasic Oral contraceptive tablet;   Drug: Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Boston Collaborative Drug Surveillance Program
Completed - verified July 2016

Non-invasive Diagnosis of Coronary Artery Stenoses by Doppler Echocardiography

Conditions:   Stable Angina Pectoris;   Unstable Angina Pectoris;   Acute Myocardial Infarction
Intervention:   Procedure: Doppler echocardiography
Sponsor:   Norwegian University of Science and Technology
Completed - verified July 2016

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

Condition:   Rheumatoid Arthritis
Intervention:   Biological: Hematopoietic Stem Cell Transplantation
Sponsor:   Northwestern University
Terminated - verified July 2016

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

Condition:   MYOPATHY
Intervention:   Biological: hematopoietic stem cell transplantation
Sponsor:   Northwestern University
Terminated - verified July 2016

Relatively Healthy Male Veterans Observed Over Time to See What Types of Diseases Develop

Condition:   Healthy
Intervention:  
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified July 2016

Beta-Blocker Heart Attack Trial (BHAT)

Conditions:   Arrhythmia;   Cardiovascular Diseases;   Coronary Disease;   Death, Sudden, Cardiac;   Heart Diseases;   Myocardial Infarction;   Myocardial Ischemia;   Ventricular Fibrillation
Intervention:   Drug: propranolol
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified October 1981

Multicenter Investigation of Limitation of Infarct Size (MILIS)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Infarction;   Myocardial Ischemia
Interventions:   Drug: propranolol;   Drug: hyaluronidase
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified December 1985